Featured

Status

Health Topics

Any Category
Diseases
Hemic and Lymphatic Diseases
Hematologic Diseases
Clear Filters

Search Clinical Trials

28 Results
Not Yet Recruiting
Zinc Supplementation in Sickle Cell Disease
The investigators propose a two-arm, double-blinded, Phase II study comparing the effects of two different daily doses of zinc (25 and 40 mg/day) in 34 patients with SCD-SS aged 15-35 …
Baylor Role: Collaborator
Recruiting
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
This is a phase I/II study of haploidentical HCT (HHCT) with ex vivo TCRαβ+ and CD19+ depletion using the CliniMACS device in patients with hematological malignancies and non-malignant disorders. HHCT …
Baylor Role: Lead Sponsor
Recruiting
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
The hemolytic uremic syndrome (HUS) is the most serious complication of high-risk Shiga toxin-producing Escherichia coli (STEC) infection and the most common cause of acquired acute kidney injury in otherwise …
Baylor Role: Collaborator
Recruiting
IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department
Iron deficiency anemia (IDA) is the most common hematologic disorder in the United States and worldwide. Patients with moderate to severe anemia often present to the acute care setting for …
Baylor Role: Lead Sponsor
Completed
Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
First, the doctor will confirm that patients are eligible for the study. Patients will complete the following procedures: - Medical history including prior hospitalizations, lab results, medications, diet, social and …
Baylor Role: Lead Sponsor
Completed
Alternate Day Versus Daily Oral Iron Therapy in Adolescents
The research will be conducted at the following location(s): Baylor College of Medicine, TCH: Texas Children's Hospital, and TCH: Texas Children's Hospital Clinic. If patient appears to qualify for the …
Baylor Role: Lead Sponsor
Recruiting
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a …
Baylor Role: Collaborator
Completed
Fetal Hemoglobin Induction Treatment Metformin
This is a dose escalation, pilot study for subjects with sickle cell anemia (SCA) disease to determine if metformin has a beneficial effect on the treatment and quality of life …
Baylor Role: Lead Sponsor
Recruiting
Investigation of the Genetics of Hematologic Diseases
Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies …
Baylor Role: Collaborator
Terminated
Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
Patients will be recruited from the patient population followed at the Texas Children's Cancer and Hematology Centers (TCC/HC)/Baylor College of Medicine (BCM) and the University of Texas Houston Hematology Center. …
Baylor Role: Lead Sponsor